v3 Template
L

Lexaria Bioscience Corp.

Biotechnology / Pharmaceuticals KELOWNA, BRITISH COLUMBIA ~340 employees
Founded
--
Employees (Est.)
~340
17 leaders known
Total Funding
$46.5M
Funding Rounds
14
Last Funding
2025-12-16

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Their proprietary DehydraTECH™ technology enhances the absorption of active pharmaceutical ingredients (APIs) into the bloodstream, improving drug effectiveness and often reducing side effects. The company focuses on healthier administration methods, lower dosing, and higher effectiveness for ingestible drugs and beneficial molecules.

Products & Services

DehydraTECH™:A patented drug delivery technology that improves absorption of bioactive compounds into the bloodstream, reduces onset time, minimizes adverse events, and enhances delivery for oral formats like tablets, capsules, and suspensions. It applies to small and large molecule therapeutics, including GLP-1 drugs.
Pharmaceutical Applications:DehydraTECH™ technology applied to pharmaceutical drugs for improved delivery and effectiveness.

Specialties

Drug Delivery Platforms Pharmacokinetics and Pharmacodynamics GLP-1 Drug Delivery Oral Drug Administration Intellectual Property in Drug Delivery

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 3500000
MR: -
FA: approximately $3.5 million
FAN: 3500000
D: 2025-12-16
FD: 2025-12-16
1 investors
2 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 3500000
MR: -
FA: $3.5 million
FAN: 3500000
D: 2025-12-15
FD: 2025-12-15
1 investors
3 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 4000000
MR: -
FA: $4.0 million
FAN: 4000000
D: 2025-09-29
FD: 2025-09-29
-
4 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 4000000
MR: -
FA: 4.0 million
FAN: 4000000
D: 2025-09-26
FD: 2025-09-26
1 investors
5 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 2000000
MR: -
FA: $2 Million
FAN: 2000000
D: 2025-04-28
FD: 2025-04-28
1 investors
6 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 2000000
MR: -
FA: $2 million
FAN: 2000000
D: 2025-04-25
FD: 2025-04-25
1 investors
7 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 5000000
MR: -
FA: approximately $5 million
FAN: 5000000
D: 2024-10-16
FD: 2024-10-16
1 investors
8 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 5000000
MR: -
FA: approximately $5 million
FAN: 5000000
D: 2024-10-15
FD: 2024-10-15
1 investors
9 RT: Warrant Exercise and Private Placement
T: -
FT: Warrant Exercise and Private Placement
A: 4700000
MR: -
FA: 4.7 million
FAN: 4700000
D: 2024-04-30
FD: 2024-04-30
2 investors
10 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 3600000
MR: -
FA: approximately $3.6 million
FAN: 3600000
D: 2024-02-16
FD: 2024-02-16
1 investors
11 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 3600000
MR: -
FA: $3.6 million
FAN: 3600000
D: 2024-02-15
FD: 2024-02-15
-
12 RT: Registered Direct Offering and Concurrent Private Placement
T: -
FT: Registered Direct Offering and Concurrent Private Placement
A: 1600000
MR: -
FA: $1.6 million
FAN: 1600000
D: 2023-09-29
FD: 2023-09-29
1 investors
13 RT: Public Offering
T: -
FT: Public Offering
A: 2000000
MR: -
FA: 2.0 million
FAN: 2000000
D: 2023-05-11
FD: 2023-05-11
-
14 RT: Public Offering
T: -
FT: Public Offering
A: 2000000
MR: -
FA: 2.0 Million
FAN: 2000000
D: 2023-05-08
FD: 2023-05-08
-
Registered Direct Offering Latest
2025-12-16
$3.5M
1 investor (Pro only)
Registered Direct Offering 2025-12-15
$3.5M
Registered Direct Offering 2025-09-29
$4.0M

View 13 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

R

Richard Christopher

CEO

J

John Docherty

Chairman

M

Michael Shankman

CFO

C

Chris Bunka

Executive Strategic Advisor

B

Bal Bhullar

CFO and Director

N

Nicholas Baxter

Member of the Board of Directors

View 14 more team members with Pro

Unlock Full Team Directory

Recent News

Lexaria Bioscience Corp. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Pharmaceuticals
Company Size
~340 employees (est.)
Locations
KELOWNA, BRITISH COLUMBIA
KELOWNA, BC
Kelowna, BC, Canada +1 more

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro